An hVIVO and Pfizer-funded human challenge trial showed high efficacy for a nucleoside-modified messenger ribonucleic acid (modRNA) influenza vaccine.
The vaccine demonstrated 100% efficacy against symptomatic influenza in the per-protocol cohort. The control group recorded a 26.9% infection rate. The modRNA vaccine also showed 100% efficacy against febrile influenza.
The vaccine reduced viral load more than the control group. Researchers reported no serious adverse events during the study.
These results support Pfizer’s continued development of mRNA influenza vaccine technology.